Results 91 to 100 of about 528,953 (331)

A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale

open access: yesIndian Dermatology Online Journal
Background: The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD.
Kabir Sardana   +4 more
doaj   +1 more source

PATHOGENETIC ROLE OF CYTOKINES IN CHILDHOOD ROTAVIRUS INFECTION

open access: yesМедицинская иммунология, 2014
. Results of cytokine network studies system in children with rotavirus infection are presented. Concentrations of cytokines were determined at both local and systemic levels.
S. N. Benyova   +2 more
doaj   +1 more source

Engineered ETS1‐Nanoconjugate Restores Immune Homeostasis through Dual Immune‐Vascular Modulation in Relapsing and Progressive Multiple Sclerosis

open access: yesAdvanced Healthcare Materials, EarlyView.
The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang   +13 more
wiley   +1 more source

Argumentation schemes for collaborative planning [PDF]

open access: yes, 2011
Postprin
A. Belesiotis   +4 more
core   +3 more sources

Th1 and Th17 cells [PDF]

open access: yesAnnals of the New York Academy of Sciences, 2010
Autoreactive effector CD4+ T cells have been associated with the pathogenesis of autoimmune disorders. Early studies implicated the interferon (IFN)‐γ‐producing T helper (Th)1 subset of CD4+ cells as the causal agents in the pathogenesis of autoimmunity. However, further studies have suggested a more complex story. In models thought to be driven by Th1
Jesse M, Damsker   +2 more
openaire   +2 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

open access: yesAdvanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang   +4 more
wiley   +1 more source

Study on the therapeutic effects of Qinghuang ointment in a mouse model of imiquimod-induced psoriasis and its underlying mechanisms

open access: yesPifu-xingbing zhenliaoxue zazhi
[Objective] To study the therapeutic effects of Qinghuang ointment on psoriasis and its underlying mechanisms in a mouse model. [Methods] Twenty-five mice were randomly assigned to the following groups: blank control group, model group, Qinghuang ...
LIU Dan   +6 more
doaj   +1 more source

The transcription factor Bhlhe40 is a switch of inflammatory versus antiinflammatory Th1 cell fate determination

open access: yesJournal of Experimental Medicine, 2017
Type 1 T helper (Th1) cells play a critical role in host defense against intracellular pathogens and in autoimmune diseases by producing a key inflammatory cytokine interferon (IFN)–&ggr;; some Th1 cells can also be antiinflammatory through producing IL ...
Fang Yu   +10 more
semanticscholar   +1 more source

Opinion: Gavage Administration of MXene as a Route‐Specific Alternative to Intravenous Injection into the Bloodstream of Laboratory Animals for Reducing Systemic Nanotoxicity Risks in Immunosuppression and Post‐Transplantation Models with Bile Acid Modification

open access: yesAdvanced Healthcare Materials, EarlyView.
Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad   +2 more
wiley   +1 more source

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

open access: yesOncoImmunology, 2019
Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood.
Katsunobu Hagihara   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy